[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Huaqiu Zhang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":108},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,63,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100597970","phase-1-treatment-of-moyamoya-disease-with-ipsc-derived-exosomes-100597970",false,"NCT07065409","Treatment of Moyamoya Disease With iPSC-derived Exosomes","Phase I Clinical Trial of Induced Pluripotent Stem Cell-derived Extracellular Vesicles Combined With Temporal Muscle Flap Application in Promoting Intracranial and Extracranial Blood Flow Reconstruction in Patients With Moyamoya Disease","Inclusion criteria:\n\n1. Diagnosed adult patients with MMD aged 18-75 years (inclusive), with bilateral terminal occlusion of the internal carotid arteries (ICA) and stenosis or occlusion of the anterior cerebral artery (ACA) and middle cerebral artery (MCA) at the origin, accompanied by the formation of abnormal vascular networks at the base of the skull, as indicated by head DSA or MRA. Unilateral or bilateral lesions are acceptable. Suzuki score ≥ 3.\n2. Relevant bone marrow, liver, kidney, and heart function indicators meet the following standards (based on the normal values of the clinical trial center): absolute neutrophil count (ANC) ≥ 1.5×109\u002FL, platelets ≥ 100×109\u002FL, total serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), ALT, AST, or ALP ≤ 3 times ULN; serum creatinine ≤ 1.5 times ULN, international normalized ratio (INR) ≤ 1.5 times ULN, APTT ≤ 1.5 times ULN.\n3. Patients have undergone temporal muscle patch surgery and have not achieved satisfactory improvement in symptoms.\n4. Patients have been followed up for ≥ 3 months since the surgery.\n5. Vascular DSA performed 3 months after the surgery indicates poor blood flow reconstruction.\n6. CTP or ASL performed 3 months after the surgery shows ischemia.\n7. Patients still have clinical manifestations of cerebral ischemia or cerebral infarction due to MMD 3 months after the surgery.\n8. Patients or their legal representatives have given informed consent and signed the informed consent form.\n\nExclusion criteria:\n\n1. Patients with severe liver or kidney dysfunction or other complications;\n2. Patients with a history of mental disorders or mental diseases;\n3. Patients with coagulation disorders;\n4. Patients with extensive cerebral infarction or in a coma;\n5. Patients who only undergo direct bypass surgery;\n6. Patients who have not signed the surgical consent form;\n7. Patients with allergic constitutions or a clear history of allergies;\n8. Pregnant women, lactating women, and patients with plans to conceive during the trial period;\n9. Patients who have participated in other clinical trials in the past three months;\n10. Patients deemed unsuitable for the trial by the researcher.","ALL","18 Years","75 Years",{"count":20,"type":21},9,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Moyamoya disease is a cerebrovascular disease clinically characterized by chronic progressive stenosis or occlusion at the ends of bilateral internal carotid arteries and the origin of anterior cerebral arteries and middle cerebral arteries, followed by the formation of abnormal vascular networks at the base of the skull. Clinically, patients with Moyamoya disease mainly present with ischemic or hemorrhagic stroke, and there are two peaks of incidence in children aged 3-5 and middle-aged people aged 40-50. Moreover, as the pathogenesis and treatment evaluation of Moyamoya disease are still in the research trough at present, new discoveries are prone to occur and thus attract a great deal of attention. It not only has a beneficial promoting effect on the treatment and diagnosis of patients, but also makes it easier for research topics to be reported in top journals.\n\nThis study intends to combine iPSC-EVs local skin transplantation with temporal muscle application to promote muscle angiogenesis and the establishment of extracranial and intracranial collateral circulation after temporal muscle application. The above-mentioned design features high efficiency, safety and convenience, and is an innovative exploration both at home and abroad. We hope to screen out safe, efficient and simple preparation methods and transplantation methods of iPSC-EVs through systematic experiments, establish an effective clinical evaluation system, and provide auxiliary means for intracranial and extracranial blood flow reconstruction surgery in the treatment of Moyamoya disease. Moreover, in terms of topic selection, iPSC is currently one of the most promising directions for innovative treatment worldwide.",[27],"Moyamoya Disease","RECRUITING","2025-09-29",{"date":31,"type":32},"2025-10-01","ACTUAL",{"date":34,"type":32},"2025-05-26",{"date":36,"type":21},"2026-10-31",{"name":38,"class":39},"Huaqiu Zhang","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100598703","an-gong-niuhuang-wan-promotes-the-postoperative-neurological-function-recovery-of-patients-with-traumatic-brain-injury-100598703","NCT07074938","An Gong Niuhuang Wan Promotes the Postoperative Neurological Function Recovery of Patients With Traumatic Brain Injury","A Non-inferiority Randomized Controlled Study Comparing Jianmin Daopeng An Gong Niuhuang Wan and Tongrentang An Gong Niuhuang Wan in Promoting the Postoperative Neurological Function Recovery of Patients With Traumatic Brain Injury","Inclusion Criteria:\n\n1. Patients with brain trauma;\n2. Age range: 18 - 60 years old (inclusive of 18 and 60);\n3. Within three days after injury (for surgical patients, starting from the time of surgery), vital signs are stable (average arterial pressure does not continuously fall below 70 mmHg, no use of vasopressor drugs; no use of invasive or non-invasive ventilators), and the condition is stable (comparison of neurological symptoms and signs at 24-hour intervals and re-examination of CT shows no significant deterioration);\n4. GCS score 6 - 12 points (inclusive of 6 and 12), with consciousness disorder;\n5. No contraindications for taking artificial or natural rhinoceros bile.\n\nExclusion Criteria:\n\n1. Have used other arousal-enhancing drugs recently;\n2. Patients with consciousness disorders caused by traditional Chinese medicine-induced cold closure of the mind;\n3. Patients with open head trauma who have a clear intracranial infection;\n4. Patients with severe complications in other organs (such as severe pneumonia, gastrointestinal bleeding, etc.);\n5. Patients who have previously suffered from other neurological diseases;\n6. Patients with severe acute or chronic diseases in various systems whose conditions have not been effectively controlled and are unstable. This includes, but is not limited to, patients with severe heart diseases such as heart function insufficiency, untreated heart failure, coronary heart disease, severe arrhythmias and other serious cardiac diseases; uncontrolled diabetes, hypertension\u002Flow blood pressure, blood system, digestive tract and respiratory system diseases, active autoimmune diseases, etc. Liver and kidney function impairment (liver function: ALT or AST ≥ 2 times the upper limit of normal, total bilirubin \\> 1.5 times the upper limit of normal; kidney function: Cr \\> 2 times the upper limit of normal); abnormal coagulation function (PT prolongation \\> 3 seconds, APTT prolongation \\> 3 seconds, platelet count \\\u003C 30 x 109\u002FL). Pregnant and lactating women;\n7. Patients who cannot undergo subsequent assessment;\n8. Patients considered unsuitable to participate in the trial by the researchers.","60 Years",{"count":50,"type":21},60,[52],"NA","Clinical Challenges and Severity of Traumatic Brain Injury: Traumatic brain injury, as a common neurosurgical disease, poses a significant threat to patients' life safety and quality of life.The promotion of in vitro cultivated cow bile in the treatment of post-traumatic brain injury is expected to provide a more economical and effective treatment option for the recovery of consciousness and cognitive functions of TBI patients. Compared with traditional An Gong Niu Huang Wan, Jian Min Da Peng's An Gong Niu Huang Wan (containing in vitro cultivated cow bile) can not only reduce treatment costs, but also improve the stability and consistency of the quality of the drug. The above clinical research can provide scientific basis for including it in relevant treatment guidelines.",[55],"Traumatic Brain Injury","2025-07-10",{"date":58,"type":32},"2025-07-20",{"date":56,"type":32},{"date":61,"type":21},"2028-07-31",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100504260","la-improves-the-prognosis-of-patients-with-icvd-100504260","NCT05845983","LA Improves the Prognosis of Patients With ICVD","Lactobacillus Acidophilus Improves the Prognosis (Cognitive Function) of Patients With Ischemic Cerebrovascular Disease After Surgery: a Multicenter, Prospective, Three-blind, Placebo-randomized Controlled Study","Inclusion Criteria:\n\n1. Between 35 and 65 years old;\n2. Han nationality;\n3. Diagnosed as ischemic cerebrovascular disease with mild to moderate symptoms;\n4. Can communicate normally, complete neuropsychological tests independently, and sign informed consent;\n5. No previous surgical history;\n6. No contraindications such as PET, MRI and DSA;\n7. No history of stroke identified by imaging;\n8. No family history of other chronic diseases, cancer, mental illness or dementia;\n9. Improved Rankin scale score ≤2;\n10. Ischemic symptoms appeared in the carotid area ≤3 months before the visit;\n11. In line with the surgical treatment of ischemic cerebrovascular disease;\n\nExclusion Criteria:\n\n1. previous dementia;\n2. hearing or visual impairment;\n3. Drugs that may or are known to influence cognitive abuse;\n4. alcohol addiction;\n5. Diagnosis of depression, schizophrenia and other psychiatric diseases;\n6. MRI showed severe cerebral infarction;\n7. Those allergic to Lactobacillus acidophilus;\n8. Baseline CT showed intracranial hemorrhage;\n9. ischemic onset accompanied by epilepsy;\n10. illiteracy;\n11. pregnancy or breastfeeding;\n12. any serious medical condition that may interact with treatment;","35 Years","65 Years",{"count":73,"type":21},236,[52],"Ischemic cerebrovascular disease will cause serious harm to the life and safety of patients, and the treatment prognosis is poor. Numerous clinical trials have demonstrated that probiotics can improve cognitive function in people under multimodal. We have previously found that Lactobacillus acidophilus administration could improve cognitive impairment in MCAO and BCAS mice. Therefore, Based on the above research background and the basis of previous studies, we believe that the administration of Lactobacillus acidophilus solid drink (pure Lactobacillus acidophilus strain) can improve the cognitive function of patients with cerebral ischemia through the \"brain-gut axis\".",[77,78,79],"Ischemia","Cerebrovascular Ischemia","Cognitive Impairment","NOT_YET_RECRUITING","2023-04-26",{"date":83,"type":32},"2023-05-06",{"date":85,"type":21},"2023-05-04",{"date":87,"type":21},"2028-12-31",{"name":38,"class":39},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":48,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":75,"conditions":98,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100489675","la-improves-the-prognosis-of-patients-with-icvd-after-surgery-100489675","NCT05656209","LA Improves the Prognosis of Patients With ICVD After Surgery","Lactobacillus Acidophilus Improves the Prognosis (Cognitive Function) of Patients With Ischemic Cerebrovascular Disease After Surgery: a Prospective Randomized Controlled Study","Inclusion Criteria:\n\n1. 35-60 years old;\n2. Diagnosed as ischemic cerebrovascular disease, mild to moderate symptoms, can independently complete the neuropsychological test;\n3. No previous operation history;\n4. The modified Rankin scale score was 0 or 1;\n5. Carotid artery ischemic symptoms ≤3 months before treatment;\n6. Surgical treatment;\n\nExclusion Criteria:\n\n1. Previous dementia;\n2. hearing or visual impairment;\n3. drugs that may or are known to affect cognitive abuse;\n4. alcohol addiction;\n5. Diagnosis of depression, schizophrenia and other mental diseases;\n6. MRI showed severe cerebral infarction;\n7. Patients with Lactobacillus acidophilus allergy.",{"count":73,"type":21},[52],[99,79],"Ischemia; Cerebrovascular","2022-12-16",{"date":102,"type":32},"2022-12-19",{"date":104,"type":21},"2022-12-18",{"date":106,"type":21},"2027-12-31",{"name":38,"class":39},""]